Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small cell lung cancer-is timing everything?

Affiliations

Editorial

Melanie P Subramanian et al. J Thorac Dis. 2019 Dec.

. 2019 Dec;11(12):5674-5676.

doi: 10.21037/jtd.2019.12.40.

¹ Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS, Yan W, Zhou J, Tan KS, Montecalvo J, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Travis WD, Kris MG, Chaft JE, Jones DR. Brandt WS, et al. J Thorac Cardiovasc Surg. 2019 Feb;157(2):743-753.e3. doi: 10.1016/j.jtcvs.2018.09.098. Epub 2018 Oct 10. J Thorac Cardiovasc Surg. 2019. PMID: 30415902 Free PMC article.

1. Ettinger DS, Aisner DL, Wood DE, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw 2018;16:807-21. 10.6004/jnccn.2018.0062 - DOI - PubMed
1. McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis 2014;6 Suppl 2:S224-7. - PMC - PubMed
1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
1. Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. J Thorac Cardiovasc Surg 2019;157:743-753.e3. 10.1016/j.jtcvs.2018.09.098 - DOI - PMC - PubMed
1. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138-45. 10.1200/JCO.2009.27.6204 - DOI - PubMed